for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ファイザー・インク

PFE.N

現在値

52.31USD

変化

-0.12(-0.23%)

出来高

5,251,607

本日のレンジ

51.26

 - 

52.37

52週レンジ

38.94

 - 

61.70

∙ 約20分前の相場を表示しています。

適時開示

Pfizer Announces Submission Of New Drug Application To The U.S. FDA For Paxlovid

June 30 (Reuters) - Pfizer Inc <PFE.N>::PFIZER ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO THE U.S. FDA FOR PAXLOVID.PFIZER - SUBMISSION SEEKS APPROVAL FOR COVID-19 TREATMENT IN VACCINATED & UNVACCINATED INDIVIDUALS AT HIGH RISK FOR PROGRESSION TO SEVERE ILLNESS.PFIZER - NDA SUBMISSION INCLUDES AVAILABLE SAFETY DATA FOR PAXLOVID GENERALLY CONSISTENT IN MORE THAN 3,500 PARTICIPANTS ACROSS EPIC CLINICAL PROGRAM.PFIZER - AS OF END OF MAY 2022, CO HAD SHIPPED MORE THAN 12 MILLION TREATMENT COURSES OF PAXLOVID TO NEARLY 40 COUNTRIES.PFIZER - NDA SUBMISSION INCLUDES DATA FROM EPIC-HR, EPIC-SR AND EPIC-PEP STUDIES WHICH SHOWED CONSISTENT REDUCTION IN VIRAL LOAD WITH PAXLOVID.PFIZER - NDA SUBMISSION INCLUDES DATA SHOWING FREQUENCY OF RETURN OF DETECTABLE NASAL VIRAL RNA FOLLOWING PAXLOVID TREATMENT WAS LOW.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).

Australia's TGA Grants Provisional Determination To Pfizer Australia For Its Covid-19 Vaccine, Comirnaty

June 30 (Reuters) - Pfizer Inc <PFE.N>::GRANTED A PROVISIONAL DETERMINATION TO PFIZER AUSTRALIA PTY LTD IN RELATION TO ITS COVID-19 VACCINE, COMIRNATY.CURRENTLY, COMIRNATY IS PROVISIONALLY APPROVED FOR USE IN INDIVIDUALS 5 YEARS OF AGE AND OLDER..PFIZER IS NOW ELIGIBLE TO APPLY FOR PROVISIONAL REGISTRATION FOR EXTENDING USE OF VACCINE TO CHILDREN AGED 6 MONTHS AND OLDER.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).

Pfizer Inc Reports 8.1% Passive Stake In Valneva SE As Of June 22

June 29 (Reuters) - Pfizer Inc <PFE.N>::PFIZER INC REPORTS 8.1% PASSIVE STAKE IN VALNEVA SE AS OF JUNE 22 - SEC FILING.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).

Biohaven Says UK Competition & Markets Authority Confirmed That No Further Information Required On Deal With Pfizer

June 28 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd <BHVN.N>::BIOHAVEN - ON JUNE 24, UK COMPETITION & MARKETS AUTHORITY CONFIRMED THAT NO FURTHER INFORMATION REQUIRED ON DEAL WITH PFIZER - FILING.Further company coverage: BHVN.N. ((Reuters.Briefs@thomsonreuters.com;)).

Roivant And Pfizer Unveil Priovant Therapeutics And Ongoing Registrational Studies For Oral Brepocitinib In Dermatomyositis And Lupus

June 28 (Reuters) - Pfizer Inc <PFE.N>::ROIVANT AND PFIZER UNVEIL PRIOVANT THERAPEUTICS AND ONGOING REGISTRATIONAL STUDIES FOR ORAL BREPOCITINIB IN DERMATOMYOSITIS AND LUPUS.PFIZER INC - AN PHASE 2B STUDY IN SLE, DESIGNED TO SERVE AS ONE OF TWO REGISTRATIONAL STUDIES, IS EXPECTED TO GENERATE TOP-LINE RESULTS IN 2H 2023.PFIZER - IN FIVE PLACEBO-CONTROLLED STUDIES COMPLETED TO DATE, ORAL BREPOCITINIB GENERATED STATISTICALLY SIGNIFICANT & CLINICALLY MEANINGFUL RESULTS.

Pfizer And Biontech Announce Omicron-Modified Covid-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

June 25 (Reuters) - Pfizer Inc. <PFE.N>::PFIZER-MONOVALENT CANDIDATE AS 4TH BOOSTER DOSE ELICITED 13.5,19.6-FOLD INCREASE IN NEUTRALIZING GEOMETRIC TITERS AGAINST BA.1 AT 30,60 MICROGRAM DOSE.PFIZER AND BIONTECH ANNOUNCE OMICRON-MODIFIED COVID-19 VACCINE CANDIDATES DEMONSTRATE HIGH IMMUNE RESPONSE AGAINST OMICRON.PFIZER - BIVALENT VACCINE CANDIDATE EXHIBITED A 9.1 AND 10.9-FOLD INCREASE IN NEUTRALIZING GEOMETRIC TITERS AGAINST BA.1.PFIZER - PRELIMINARY LABORATORY STUDIES DEMONSTRATE BOTH OMICRON-MODIFIED CANDIDATES NEUTRALIZE BA.4, BA.5 THOUGH TO LESSER EXTENT THAN THEY DO FOR BA.1.PFIZER - GEOMETRIC MEAN RATIOS FOR OMICRON NEUTRALIZING ANTIBODY RESPONSE CONSISTENT WITH REGULATORY REQUIREMENT OF SUPERIORITY.PFIZER - BOTH VACCINE CANDIDATES DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE SIMILAR TO THE PFIZER-BIONTECH COVID-19 VACCINE.PFIZER - DATA TO BE DISCUSSED WITH REGULATORS WITH GOAL OF RAPIDLY INTRODUCING MODIFIED BOOSTER TO ADDRESS CURRENT AND FUTURE VARIANTS.

Valneva, Pfizer Finalise Equity Investment

June 23 (Reuters) - Valneva SE <VLS.PA>::VALNEVA AND PFIZER ANNOUNCE CLOSING OF EQUITY INVESTMENT.PFIZER HAS INVESTED EUR 90.5 ($95) MILLION IN VALNEVA, REPRESENTING 8.1% OF VALNEVA'S SHARE CAPITAL AT A PRICE OF EUR 9.49 PER SHARE, THROUGH A RESERVED CAPITAL INCREASE.PFIZER PLANS TO INITIATE PHASE 3 STUDY OF VLA15 IN Q3 OF 2022.VALNEVA IS PLANNING TO USE PROCEEDS TO SUPPORT ITS CONTRIBUTION TO PLANNED PHASE 3 DEVELOPMENT PROGRAM FOR LYME DISEASE VACCINE CANDIDATE VLA15.

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer

June 21 (Reuters) - Enanta Pharmaceuticals Inc <ENTA.O>::PRESS RELEASE- ENANTA PHARMACEUTICALS FILES PATENT INFRINGEMENT SUIT AGAINST PFIZER.ENANTA PHARMACEUTICALS INC - SEEKS FAIR COMPENSATION FOR PFIZER'S USE OF A CORONAVIRUS 3CL PROTEASE INHIBITOR CLAIMED IN '953 PATENT.ENANTA - SEEKING DAMAGES FOR INFRINGEMENT OF '953 PATENT IN MANUFACTURE, USE,SALE OF PFIZER'S COVID-19 ANTIVIRAL, PAXLOVID.

FDA Authorizes Moderna And Pfizer-Biontech Covid-19 Vaccines For Children Down To 6 Months Of Age

June 17 (Reuters) - FDA::FDA AUTHORIZES MODERNA AND PFIZER-BIONTECH COVID-19 VACCINES FOR CHILDREN DOWN TO 6 MONTHS OF AGE.FDA - FOR THE PFIZER-BIONTECH COVID-19 VACCINE, THE FDA AMENDED THE EUA TO INCLUDE USE OF THE VACCINE IN INDIVIDUALS 6 MONTHS THROUGH 4 YEARS OF AGE.FDA - FOR MODERNA COVID-19 VACCINE, AMENDED EUA TO INCLUDE USE OF THE VACCINE IN INDIVIDUALS 6 MONTHS THROUGH 17 YEARS OF AGE.FDA - THE MODERNA COVID-19 VACCINE IS ADMINISTERED AS A PRIMARY SERIES OF TWO DOSES, ONE MONTH APART, TO INDIVIDUALS 6 MONTHS THROUGH 17 YEARS OF AGE.FDA - PFIZER-BIONTECH COVID-19 VACCINE IS ADMINISTERED AS A PRIMARY SERIES OF THREE DOSES.Further company coverage: [22UAy.DE]. ((Reuters.Briefs@thomsonreuters.com;)).

Basilea Pharmaceutica: Cresemba Sales In Asia Pacific Trigger Milestone Payment From Pfizer

June 17 (Reuters) - BASILEA PHARMACEUTICA AG <BSLN.S>::CRESEMBA® SALES IN ASIA PACIFIC REGION TRIGGER SALES MILESTONE PAYMENT TO BASILEA FROM PFIZER.BASILEA PHARMACEUTICA AG - SALES OF ANTIFUNGAL CRESEMBA BY ITS LICENSE PARTNER PFIZER INC. IN ASIA PACIFIC REGION EXCEEDED THRESHOLD TRIGGERING FIRST SALES MILESTONE PAYMENT FOR THIS REGION OF USD 1.25 MILLION.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up